ArticleNeuro-oncology advances
Blood group O attributes to prolonged progression-free survival, overall survival, and 5-year survival in isocitrate dehydrogenase-wildtype glioblastoma patients with MGMT promoter methylation.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) remains incurable despite multimodal therapeutic approaches. Here, we assessed the relevance of ABO blood groups for progression-free survival (PFS), overall survival (OS), and long-term survival in a large cohort of isocitrate dehydrogenase (IDH)-wildtype (wt) GBM patients. Methods: Consecutive GBM patients (2009-2020) at a large tertiary brain tumor center were included, and clinical data were retrospectively abstracted. We dichotomized patients into those with blood group O and those with a Non-O blood group. Patient, tumor, and treatment characteristics were compared between these groups. Association with outcomes was assessed in univariable and multivariable settings via log-rank tests and Cox proportional hazards regressions, respectively. Results: Five hundred fifty-four GBM IDH-wt had available ABO information. There were no substantial differences in patient, tumor, or treatment characteristics between group O and group Non-O. In contrast, blood group O patients showed increased PFS, OS, and 5-year survivals in both univariable and multivariable analyses. Differences were strongly pronounced in patients with MGMT promoter methylated tumors receiving standardized radiochemotherapy (OS blood group O 24.6 months [95%CI 17.8-31.4] vs Non-O 17.7 months [14.1-21.3], Conclusion: Blood group O status in conjunction with MGMT promoter methylation (including weak methylation) is an independent favorable prognostic marker in GBM IDH-wt patients receiving standardized radiochemotherapy. This finding is unprecedented, suggesting a linkage between the downregulation of a DNA repair protein and the absence of a functional blood cell surface glycosyltransferase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.